These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
3. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Wels W; Biburger M; Müller T; Dälken B; Giesübel U; Tonn T; Uherek C Cancer Immunol Immunother; 2004 Mar; 53(3):217-26. PubMed ID: 14704833 [TBL] [Abstract][Full Text] [Related]
4. Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor. Wels W; Harwerth IM; Hynes NE; Groner B J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):1-7. PubMed ID: 1381944 [TBL] [Abstract][Full Text] [Related]
5. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Argyriou AA; Kalofonos HP Mol Med; 2009; 15(5-6):183-91. PubMed ID: 19305491 [TBL] [Abstract][Full Text] [Related]
6. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Hu S; Fu W; Xu W; Yang Y; Cruz M; Berezov SD; Jorissen D; Takeda H; Zhu W Cancer Res; 2015 Jan; 75(1):159-70. PubMed ID: 25371409 [TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Roskoski R Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Modjtahedi H; Eccles S; Box G; Styles J; Dean C Br J Cancer; 1993 Feb; 67(2):254-61. PubMed ID: 7679281 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163 [TBL] [Abstract][Full Text] [Related]
12. Development of monoclonal antibodies for the treatment of colorectal cancer. Goodin S Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S3-7; quiz S22-4. PubMed ID: 18499888 [TBL] [Abstract][Full Text] [Related]
13. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
14. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. Heitner T; Moor A; Garrison JL; Marks C; Hasan T; Marks JD J Immunol Methods; 2001 Feb; 248(1-2):17-30. PubMed ID: 11223066 [TBL] [Abstract][Full Text] [Related]
15. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702 [TBL] [Abstract][Full Text] [Related]